Evotec (EVO) Competitors

Evotec logo
$1.48 -0.08 (-5.13%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EVO vs. ALMR, FTRE, MRVI, BLFS, and AZTA

Should you buy Evotec stock or one of its competitors? Evotec's main competitors and comparable companies include Alamar Biosciences (ALMR), Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), and Azenta (AZTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Evotec compare to Alamar Biosciences?

Evotec (NASDAQ:EVO) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

5.8% of Evotec shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Evotec currently has a consensus price target of $3.50, suggesting a potential upside of 124.36%. Alamar Biosciences has a consensus price target of $33.00, suggesting a potential upside of 8.02%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evotec
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Alamar Biosciences
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Evotec has a net margin of -26.20% compared to Alamar Biosciences' net margin of -48.22%. Evotec's return on equity of -24.93% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evotec-26.20% -24.93% -11.35%
Alamar Biosciences -48.22%-78.71%-20.08%

Alamar Biosciences has lower revenue, but higher earnings than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec$891.97M0.62-$117.12MN/AN/A
Alamar Biosciences$74.21M28.60-$29.82M-$2.15N/A

In the previous week, Alamar Biosciences had 2 more articles in the media than Evotec. MarketBeat recorded 7 mentions for Alamar Biosciences and 5 mentions for Evotec. Alamar Biosciences' average media sentiment score of 0.71 beat Evotec's score of 0.49 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evotec
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alamar Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Evotec and Alamar Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Evotec compare to Fortrea?

Evotec (NASDAQ:EVO) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

5.8% of Evotec shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fortrea has a net margin of -2.58% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 13.98% beat Evotec's return on equity.

Company Net Margins Return on Equity Return on Assets
Evotec-26.20% -24.93% -11.35%
Fortrea -2.58%13.98%2.76%

Evotec has higher earnings, but lower revenue than Fortrea.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec$891.97M0.62-$117.12MN/AN/A
Fortrea$2.72B0.70-$986.20M-$0.73N/A

In the previous week, Fortrea had 6 more articles in the media than Evotec. MarketBeat recorded 11 mentions for Fortrea and 5 mentions for Evotec. Fortrea's average media sentiment score of 0.58 beat Evotec's score of 0.49 indicating that Fortrea is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evotec
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortrea
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Evotec presently has a consensus target price of $3.50, indicating a potential upside of 124.36%. Fortrea has a consensus target price of $24.23, indicating a potential upside of 22.42%. Given Evotec's higher possible upside, equities analysts plainly believe Evotec is more favorable than Fortrea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evotec
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46

Evotec has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Summary

Fortrea beats Evotec on 11 of the 15 factors compared between the two stocks.

How does Evotec compare to Maravai LifeSciences?

Evotec (NASDAQ:EVO) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

In the previous week, Maravai LifeSciences had 1 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Maravai LifeSciences and 5 mentions for Evotec. Maravai LifeSciences' average media sentiment score of 0.95 beat Evotec's score of 0.49 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evotec
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maravai LifeSciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Evotec has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

5.8% of Evotec shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evotec has higher revenue and earnings than Maravai LifeSciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec$891.97M0.62-$117.12MN/AN/A
Maravai LifeSciences$185.74M10.36-$130.77M-$0.43N/A

Evotec currently has a consensus price target of $3.50, indicating a potential upside of 124.36%. Maravai LifeSciences has a consensus price target of $8.10, indicating a potential upside of 9.46%. Given Evotec's higher probable upside, equities research analysts clearly believe Evotec is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evotec
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Maravai LifeSciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

Evotec has a net margin of -26.20% compared to Maravai LifeSciences' net margin of -30.83%. Maravai LifeSciences' return on equity of -12.44% beat Evotec's return on equity.

Company Net Margins Return on Equity Return on Assets
Evotec-26.20% -24.93% -11.35%
Maravai LifeSciences -30.83%-12.44%-6.66%

Summary

Maravai LifeSciences beats Evotec on 10 of the 15 factors compared between the two stocks.

How does Evotec compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

BioLife Solutions has higher earnings, but lower revenue than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$106.69M17.71-$4.59M$1.1633.28
Evotec$891.97M0.62-$117.12MN/AN/A

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions53.29% 2.70% 2.49%
Evotec -26.20%-24.93%-11.35%

In the previous week, Evotec had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for Evotec and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.13 beat Evotec's score of 0.49 indicating that BioLife Solutions is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLife Solutions
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evotec
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioLife Solutions has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Evotec has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioLife Solutions presently has a consensus target price of $31.38, suggesting a potential downside of 18.74%. Evotec has a consensus target price of $3.50, suggesting a potential upside of 124.36%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09
Evotec
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

BioLife Solutions beats Evotec on 9 of the 13 factors compared between the two stocks.

How does Evotec compare to Azenta?

Evotec (NASDAQ:EVO) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Evotec presently has a consensus target price of $3.50, indicating a potential upside of 124.36%. Azenta has a consensus target price of $47.60, indicating a potential upside of 0.80%. Given Evotec's higher possible upside, equities research analysts plainly believe Evotec is more favorable than Azenta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evotec
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Azenta had 40 more articles in the media than Evotec. MarketBeat recorded 45 mentions for Azenta and 5 mentions for Evotec. Azenta's average media sentiment score of 0.57 beat Evotec's score of 0.49 indicating that Azenta is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evotec
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Azenta
7 Very Positive mention(s)
7 Positive mention(s)
19 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

5.8% of Evotec shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Azenta has lower revenue, but higher earnings than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec$891.97M0.62-$117.12MN/AN/A
Azenta$621.70M3.33-$55.76M-$3.62N/A

Evotec has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market. Comparatively, Azenta has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Evotec has a net margin of -26.20% compared to Azenta's net margin of -26.86%. Azenta's return on equity of 1.41% beat Evotec's return on equity.

Company Net Margins Return on Equity Return on Assets
Evotec-26.20% -24.93% -11.35%
Azenta -26.86%1.41%1.15%

Summary

Azenta beats Evotec on 10 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVO vs. The Competition

MetricEvotecLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$526.61M$10.75B$7.74B$11.62B
Dividend YieldN/A1.45%2.46%4.43%
P/E RatioN/A51.1234.1629.83
Price / Sales0.598.348.485.62
Price / CashN/A26.6921.9322.50
Price / Book0.714.454.373.66
Net Income-$117.12M$57.48B$3.52B$392.18M
7 Day Performance-12.43%-4.85%-5.43%-4.26%
1 Month Performance7.25%-1.00%-4.54%-6.73%
1 Year Performance-50.00%20.94%-1.42%-7.08%

Evotec Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVO
Evotec
2.8925 of 5 stars
$1.48
-5.1%
$3.50
+136.5%
-48.3%$526.61M$891.97MN/A4,553
ALMR
Alamar Biosciences
2.2088 of 5 stars
$31.48
-1.1%
$33.00
+4.8%
N/A$2.18B$74.21MN/A222
FTRE
Fortrea
4.189 of 5 stars
$21.30
-4.2%
$23.95
+12.5%
+90.1%$2.06B$2.72BN/A14,300
MRVI
Maravai LifeSciences
1.8979 of 5 stars
$7.66
-4.6%
$7.38
-3.7%
+103.3%$1.99B$185.74MN/A410
BLFS
BioLife Solutions
1.554 of 5 stars
$38.61
flat
$31.38
-18.7%
N/A$1.89B$106.69M33.28440

Related Companies and Tools


This page (NASDAQ:EVO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners